Literature DB >> 11730631

[Smoking-attributable deaths in Spain in 1998].

J R Banegas Banegas1, L Díez Gañán, F Rodríguez-Artalejo, J González Enríquez, A Graciani Pérez-Regadera, F Villar Alvarez.   

Abstract

BACKGROUND: Between 1993 and 1997, smoking prevalence remained stable in Spain yet age-adjusted death rates by smoking-related diseases decreased. Our study aimed to estimate the burden of smoking-attributable mortality in Spain in 1998. POPULATION AND
METHOD: Spain's smoking prevalence, mortality and relative risks for death from the Cancer Prevention Study II were used to estimate smoking-attributable mortality in the population aged 35 years and over.
RESULTS: In 1998, 55,613 deaths were attributable to smoking. One out of 4 deaths in males and one out of 40 deaths in females were attributable to tobacco. Two thirds of the attributable mortality corresponded to deaths due to lung cancer, chronic obstructive pulmonary disease, ischemic heart disease and stroke.
CONCLUSIONS: Smoking actually represents a remarkable burden of avoidable deaths in Spain. Smoking-attributable mortality appears to continue increasing in the last years.

Entities:  

Mesh:

Year:  2001        PMID: 11730631     DOI: 10.1016/s0025-7753(01)72226-9

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  10 in total

1.  One year effectiveness of an individualised smoking cessation intervention at the workplace: a randomised controlled trial.

Authors:  F Rodríguez-Artalejo; P Lafuente Urdinguio; P Guallar-Castillón; P Garteizaurrekoa Dublang; O Sáinz Martínez; J I Díez Azcárate; M Foj Alemán; J R Banegas
Journal:  Occup Environ Med       Date:  2003-05       Impact factor: 4.402

2.  [Doctor, I want to give up smoking].

Authors:  M Torrecilla García
Journal:  Aten Primaria       Date:  2002-09-30       Impact factor: 1.137

3.  [Recommendations on the diagnostic and therapeutic approach to smokers. Consensus document].

Authors:  M Torrecilla García; F Domínguez Grandal; A Torres Lana; C Cabezas Peña; C A Jiménez Ruiz; M Barrueco Ferrero; S Solano Reina; J I de Granda Orive; J L Díaz-Maroto Muñoz; J Alonso; M L Martínez; S García; E de la Cruz Amorós; R Abengozar Muela; F Ramos Postigo; J Ayesta
Journal:  Aten Primaria       Date:  2002-09-30       Impact factor: 1.137

4.  [Ethical approaches to treating tobacco dependency].

Authors:  R Córdoba García; C Sanz Andrés
Journal:  Aten Primaria       Date:  2005-06-30       Impact factor: 1.137

5.  A randomised controlled trial of motivational interviewing for smoking cessation.

Authors:  Raimundo Soria; Almudena Legido; Concepión Escolano; Ana López Yeste; Julio Montoya
Journal:  Br J Gen Pract       Date:  2006-10       Impact factor: 5.386

6.  Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenarios.

Authors:  C P Wen; S P Tsai; C-J Chen; T Y Cheng; M-C Tsai; D T Levy
Journal:  Tob Control       Date:  2005-06       Impact factor: 7.552

7.  [Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care].

Authors:  Antoni Sicras Mainar; Ruth Navarro Artieda; Silvia Díaz Cerezo; Belén Martí Sánchez; Verónica Sanz De Burgoa
Journal:  Aten Primaria       Date:  2011-03-05       Impact factor: 1.137

8.  [Smoking cessation in primary and specialized care: a real opportunity and a public health necessity].

Authors:  M Torrecilla García; M Barrueco; J A Maderuelo; C Jiménez Ruiz; M D Plaza Martín; M A Hernández Mezquita
Journal:  Aten Primaria       Date:  2002-09-15       Impact factor: 1.137

9.  Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.

Authors:  Marta Trapero-Bertran; Celia Muñoz; Kathryn Coyle; Doug Coyle; Adam Lester-George; Reiner Leidl; Bertalan Németh; Kei-Long Cheung; Subhash Pokhrel; Ángel Lopez-Nicolás
Journal:  Addiction       Date:  2018-03-13       Impact factor: 6.526

10.  Effectiveness of spirometry as a motivational tool for smoking cessation: a clinical trial, the ESPIMOAT study.

Authors:  María Isabel Irizar-Aramburu; Jose Manuel Martínez-Eizaguirre; Petra Pacheco-Bravo; Maria Diaz-Atienza; Iñigo Aguirre-Arratibel; Maria Isabel Peña-Peña; Mercedes Alba-Latorre; Mikel Galparsoro-Goikoetxea
Journal:  BMC Fam Pract       Date:  2013-12-05       Impact factor: 2.497

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.